Acrivon Therapeutics, Inc. (ACRV) has shared an update.
On April 24, 2024, the Company announced promising clinical trial results for ACR-368, showing a 50% response rate in patients with specific cancer markers, and stability in other patients when combined with a low-dose drug. Alongside this, the Company’s virtual R&D event highlighted their financial health, with a substantial cash balance indicating funding secured until the latter part of 2026. This combination of scientific advancement and strong financial positioning suggests a positive trajectory for the Company’s future endeavors in cancer treatment.
For detailed information about ACRV stock, go to TipRanks’ Stock Analysis page.
